Amunix Pharmaceuticals Inc.
500 Ellis Street
About Amunix Pharmaceuticals Inc.
Building Better Therapeutics
Amunix is an industry leader in the discovery and development of long-acting protein-based therapeutics. Amunix’ pipeline products are based on our proprietary XTEN® half-life extension, Antibody-XTEN-Drug Conjugate and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these technologies over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with leading biotechnology and pharma companies.
29 articles with Amunix Pharmaceuticals Inc.
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS
Amunix Pharmaceuticals, Inc. announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.
Nearly two months after inking a licensing deal worth up to $1.5 billion with Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round.
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing pro-drugs to enable the promise of potent immune-activating biotherapeutics in solid tumors, today announced that it has provided a technology license to F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”) to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets
Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors
Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors.
Amunix, Inc. Release: IND Submission To Initiate Clinical Trials Of NB 1001 (XTEN-GLP1) For Treatment Of Short Bowel Syndrome Announced By Naia Rare Diseases
Amunix, Inc. And PolyPeptide Laboratories Inc. Enter Into Partnership To Produce XTEN Peptide Conjugates For Evaluation By Third Parties For Pharmaceutical Therapeutics
Amunix, Inc. Signs A Services And Supply Agreement With The University Of Nebraska-Lincoln To Produce GMP-Grade XTEN For Pharmaceutical Therapeutics
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal
Amunix, Inc. Presents XTEN Half-Life Extension Technology At Next Generation Protein Therapeutics Summit